GenSight Biologics Closes EUR 1 Million Fundraising Backed by Existing Shareholders
GenSight Biologics closed its EUR 1 million fundraising, announced October 8, 2026, with support from existing shareholders. The offering included 2,597,404 ordinary shares, admitted to trading on Euronext Paris on October 12, 2026. It also included 11,940,300 pre-funded warrants exercisable for 11,940,300 additional o